Fostemsavir vs YASO GEL
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV gp120 · full HIV pipeline
Fostemsavir · Rukobia
Marketed by GlaxoSmithKline
NCT02362503 · Phase 3 · active, not recruiting
The randomized, double-blind comparison against placebo was statistically clear (p<0.0001), but the primary endpoint was the short-term change in viral load at Day 8, a pharmacodynamic measure of antiviral activity rather than sustained viral suppression. Only 270 participants entered the randomized comparison, and the rest of the study, including the non-randomized cohort and the long-term follow-up, was open label.
Next expected readout: January 2027 · NCT07053384 (registry estimate)
Reported efficacy
Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007) (met)
Result source: NCT02362503
YASO GEL
Developed by Yaso Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fostemsavir | YASO GEL |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 72% vs 75%vs ATV/rNCT0138473411 other results
| —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT02362503 | —Not reported |
| CD4 count, change (week 48) | 211.7 vs 250.1vs ATV/rNCT0138473411 other results
| —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- Fostemsavir
- 72% vs 75%vs ATV/rNCT01384734
11 other results
- 69% vs 75% NCT01384734
- 76% vs 75% NCT01384734
- 80% vs 75% NCT01384734
- 58% vs 57% NCT01384734
- 68% vs 71% NCT01384734
- 49% vs 57% NCT01384734
- 61% vs 71% NCT01384734
- 63% vs 57% NCT01384734
- 69% vs 71% NCT01384734
- 78% vs 57% NCT01384734
- 82% vs 71% NCT01384734
- YASO GEL
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Fostemsavir
- —Trial running · NCT02362503
- YASO GEL
- —Not reported
CD4 count, change (week 48)
- Fostemsavir
- 211.7 vs 250.1vs ATV/rNCT01384734
11 other results
- 155.4 vs 178.7 NCT01384734
- 124.5 vs 119.4 NCT01384734
- 210.8 vs 250.1 NCT01384734
- 158.7 vs 178.7 NCT01384734
- 111 vs 119.4 NCT01384734
- 175.7 vs 250.1 NCT01384734
- 140.5 vs 178.7 NCT01384734
- 109.5 vs 119.4 NCT01384734
- 264.6 vs 250.1 NCT01384734
- 199.1 vs 178.7 NCT01384734
- 134.3 vs 119.4 NCT01384734
- YASO GEL
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
YASO GEL: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Fostemsavir: 4 of 4 rows · YASO GEL: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fostemsavir |
|---|---|
| Dropout rate | —600 mg BIDa NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 show 10 more results2%600 mg BID NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 56%1200 mg QD NCT01384734 · Phase 2 · combination 49%800 mg BID NCT01384734 · Phase 2 · combination 45.1%600 mg QD NCT01384734 · Phase 2 · combination 34%400 mg BID NCT01384734 · Phase 2 · combination 0%1200 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence 0%1200 mg Q12H + RTV 100 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence · combination 0%1200 mg Q12H + RTV 100 mg QAM NCT01009814 · Phase 2 · registry result, not featured evidence · combination 10%1200 mg QHS + RTV 100 mg QHS NCT01009814 · Phase 2 · registry result, not featured evidence · combination 10%600 mg Q12H + RTV 100 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —600 mg BIDa NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 show 10 more results1%600 mg BID NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 4%1200 mg QD NCT01384734 · Phase 2 · combination 6.1%800 mg BID NCT01384734 · Phase 2 · combination 0%600 mg QD NCT01384734 · Phase 2 · combination 0%400 mg BID NCT01384734 · Phase 2 · combination —1200 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence —1200 mg Q12H + RTV 100 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence · combination —1200 mg Q12H + RTV 100 mg QAM NCT01009814 · Phase 2 · registry result, not featured evidence · combination —1200 mg QHS + RTV 100 mg QHS NCT01009814 · Phase 2 · registry result, not featured evidence · combination —600 mg Q12H + RTV 100 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 48.5%600 mg BIDa NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 show 10 more results2%600 mg BID NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 —1200 mg QD NCT01384734 · Phase 2 · combination —800 mg BID NCT01384734 · Phase 2 · combination —600 mg QD NCT01384734 · Phase 2 · combination —400 mg BID NCT01384734 · Phase 2 · combination 0%1200 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence 0%1200 mg Q12H + RTV 100 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence · combination 0%1200 mg Q12H + RTV 100 mg QAM NCT01009814 · Phase 2 · registry result, not featured evidence · combination 0%1200 mg QHS + RTV 100 mg QHS NCT01009814 · Phase 2 · registry result, not featured evidence · combination 0%600 mg Q12H + RTV 100 mg Q12H NCT01009814 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 600 mg BIDa diarrhoea 25.3% (placebo 4.3%) nausea 21.2% (placebo 5.8%) nasopharyngitis 19.2% (placebo 0%) NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 show 6 more results600 mg BID nausea 6.9% (placebo 5.8%) diarrhoea 3.9% (placebo 4.3%) headache 3% (placebo 7.2%) NCT02362503 · Phase 3 · monotherapy · HIV · phase 3 1200 mg Q12H headache 40% micturition urgency 30% diarrhoea 20% NCT01009814 · Phase 2 · registry result, not featured evidence 1200 mg Q12H + RTV 100 mg Q12H headache 40% nasopharyngitis 30% rash 20% NCT01009814 · Phase 2 · registry result, not featured evidence · combination 1200 mg Q12H + RTV 100 mg QAM headache 30% erythema 20% nasopharyngitis 20% NCT01009814 · Phase 2 · registry result, not featured evidence · combination 1200 mg QHS + RTV 100 mg QHS headache 30% discomfort 10% influenza like illness 10% NCT01009814 · Phase 2 · registry result, not featured evidence · combination 600 mg Q12H + RTV 100 mg Q12H headache 40% rash 20% asthenia 10% NCT01009814 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 9 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fostemsavir
show 12 more results
show 11 more results
show 24 more results
show 3 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fostemsavir's landscape · YASO GEL's landscape